Glen H Hall
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Glen H Hall has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Stephen Lawrence Atkin
Royal College of Surgeons in Ireland, Busaiteen, Bahrain
2 shared publications I Richmond
Department of Pathology, Hull Royal Infirmary, Anlaby Road, Hull, HU3 2JZ, UK
1 shared publicationL Helboe
Neurobiology, H. Lundbeck A/S, Ottiliavej 7, DK-2500 Valby, Denmark
1 shared publicationL W Turnbull
Department of Radiology, University of Hull, Centre for Magnetic Resonance Investigations, Hull Royal Infirmary, Anlaby Road, Hull, HU3 2JZ, UK
1 shared publicationLindsay W Turnbull
1 shared publication
Latest Publications
- Open Access
- 25 June 2002
- Published by Springer Nature in British Journal of Cancer
- Vol. 87 (1) , 86-90
Localisation of somatostatin and somatostatin receptors in benign and malignant ovarian tumours
Somatostatin has been identified as having anti-proliferative, anti-angiogenic and pro-apoptotic actions in many tumour systems, and these effects are mediated through a family of five transmembrane G-protein coupled SRIF receptors. Ovarian cancer is the commonest gynaecological malignancy in the UK and maintenance therapy is urgently required. Native somatostatin expression and its receptors sst1,2,3 and 5 were studied with immunohistochemistry in 63 malignant and 35 benign ovarian tumours of various histological types. Fifty-seven out of 63 (90%) of malignant and 26/35 (74%) benign tumours expressed somatostatin. Receptors sst1,2,3 and 5 were expressed variably in epithelial, vascular and stromal compartments for both benign and malignant tumours. Somatostatin was found to correlate significantly with stromal sst1 (P=0.008), epithelial sst1 (P2 (P=0.019), vascular sst2 (P=0.026), epithelial sst3 (P=0.026), stromal sst5 (P=0.013) and vascular sst5 (P=0.038). Increased expression of native somatostatin correlating with somatostatin receptors in malignant ovarian tumours raises the possibility that either synthetic somatostatin antagonists or receptor agonists may have therapeutic potential.
- 25 June 2002
- Published by Springer Nature in British Journal of Cancer
- Vol. 87 (1) , 86-90
Open AccessLocalisation of somatostatin and somatostatin receptors in benign and malignant ovarian tumours
Somatostatin has been identified as having anti-proliferative, anti-angiogenic and pro-apoptotic actions in many tumour systems, and these effects are mediated through a family of five transmembrane G-protein coupled SRIF receptors. Ovarian cancer is the commonest gynaecological malignancy in the UK and maintenance therapy is urgently required. Native somatostatin expression and its receptors sst1,2,3 and 5 were studied with immunohistochemistry in 63 malignant and 35 benign ovarian tumours of various histological types. Fifty-seven out of 63 (90%) of malignant and 26/35 (74%) benign tumours expressed somatostatin. Receptors sst1,2,3 and 5 were expressed variably in epithelial, vascular and stromal compartments for both benign and malignant tumours. Somatostatin was found to correlate significantly with stromal sst1 (P=0.008), epithelial sst1 (P2 (P=0.019), vascular sst2 (P=0.026), epithelial sst3 (P=0.026), stromal sst5 (P=0.013) and vascular sst5 (P=0.038). Increased expression of native somatostatin correlating with somatostatin receptors in malignant ovarian tumours raises the possibility that either synthetic somatostatin antagonists or receptor agonists may have therapeutic potential.
- 1 February 2002
- Vol. 47 (2) , 107-14
Use of dynamic contrast-enhanced MRI to assess the functional vascular pharmacokinetic parameters of normal human ovaries.
To assess the ability of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) to measure functional vascular pharmacokinetic parameters of normal human ovaries in vivo using an open linear two-compartment pharmacokinetic model. Twenty-one women with no ovarian disease underwent DCE-MRI. Sequential images were acquired during injection of a contrast bolus. Ovarian volumes were calculated and pharmacokinetic data analyzed using a pharmacokinetic model. Ovarian tissue was compared with skeletal muscle to demonstrate the pharmacokinetic parameters. Normal ovarian tissue was found to enhance rapidly and dramatically. When compared with skeletal muscle as a control, ovarian tissue was seen to demonstrate a significantly higher maximum enhancement factor and amplitude of the upslope, although there was no significant difference in the exchange rate. Sample size precluded conclusions about differences due to menstrual cycle or menopausal status. The results reflect the vascular physiology of the normal ovary. Definition of the pharmacokinetic properties of normal ovaries will allow DCE-MRI to be applied prospectively to conduct noninvasive, in vivo studies of ovarian angiogenic function, including response to drugs, contraceptive research, assessment of polycystic ovary syndrome, ovarian hyperstimulation syndrome, diagnosis of malignancy and prediction of response to antiangiogenic chemotherapy.
- 1 February 2002
- Vol. 47 (2) , 107-14
Use of dynamic contrast-enhanced MRI to assess the functional vascular pharmacokinetic parameters of normal human ovaries.
To assess the ability of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) to measure functional vascular pharmacokinetic parameters of normal human ovaries in vivo using an open linear two-compartment pharmacokinetic model. Twenty-one women with no ovarian disease underwent DCE-MRI. Sequential images were acquired during injection of a contrast bolus. Ovarian volumes were calculated and pharmacokinetic data analyzed using a pharmacokinetic model. Ovarian tissue was compared with skeletal muscle to demonstrate the pharmacokinetic parameters. Normal ovarian tissue was found to enhance rapidly and dramatically. When compared with skeletal muscle as a control, ovarian tissue was seen to demonstrate a significantly higher maximum enhancement factor and amplitude of the upslope, although there was no significant difference in the exchange rate. Sample size precluded conclusions about differences due to menstrual cycle or menopausal status. The results reflect the vascular physiology of the normal ovary. Definition of the pharmacokinetic properties of normal ovaries will allow DCE-MRI to be applied prospectively to conduct noninvasive, in vivo studies of ovarian angiogenic function, including response to drugs, contraceptive research, assessment of polycystic ovary syndrome, ovarian hyperstimulation syndrome, diagnosis of malignancy and prediction of response to antiangiogenic chemotherapy.